Literature DB >> 6689126

Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure).

S Ward, E A Neill.   

Abstract

The pharmacokinetic profile of atracurium was examined in six patients with acute hepatic and renal failure and compared with that in six normal patients after an i.v. bolus (mean dose 0.7 mg kg-1). The plasma concentrations were measured by high pressure liquid chromatography and the data fitted to a two-compartment pharmacokinetic model. The results from the two groups were not significantly different, giving a mean plasma elimination half-life of 22 min in patients with severe hepatic and renal failure and a mean of 21 min in the normal group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6689126     DOI: 10.1093/bja/55.12.1169

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  12 in total

1.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Quantitative determination of atracurium in human plasma using high-performance liquid chromatography.

Authors:  R Okutani; K Kono; F M DeBros; D M Philbin
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

Review 3.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 4.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 5.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

6.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

7.  Dose requirements of continuous infusion of rocuronium and atracurium throughout orthotopic liver transplantation in humans.

Authors:  Xiao-Chuan Weng; Liang Zhou; Yin-Yan Fu; Sheng-Mei Zhu; Hui-Liang He; Jian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

8.  Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation.

Authors:  J F Bion; M I Bowden; B Chow; L Honisberger; B C Weatherley
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

9.  Atracurium for short surgical procedures: a comparison with succinylcholine.

Authors:  H K Gyasi; M Naguib; Y Adu-Gyamfi
Journal:  Can Anaesth Soc J       Date:  1985-11

Review 10.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.